Dr. Ronald Matteotti is redefining how cancer expertise reaches patients. A triple board-certified surgeon and global medical affairs leader, Matteotti has spent more than two decades driving innovation in pancreatic and liver cancer care. At Trusted Telehealth®, he’s aligning science, empathy, and strategy for patients worldwide to make obtaining a second opinion an easy and accessible process.
While breakthroughs in oncology are accelerating, access to them remains uneven. That realization inspired his focus on redefining how second opinions in cancer care are delivered. “The intersection of clinical leadership and digital innovation is where transformation happens. Advancing cancer care requires the synergy of science, strategy, and empathy,” says Matteotti.
Reimagining the Cancer Second Opinion
Obtaining a second opinion can be an arduous process that can take weeks, involve cross-country travel, and lead to conflicting recommendations. “That uncertainty can be devastating,” Matteotti says. “When every moment counts, patients deserve better.”
Trusted Telehealth’s physician-led, AI-supported platform, ISMIOS™, was built to change that. Designed to provide rapid access to subspecialty oncology experts across the United States, the system delivers expert reviews in days, not weeks. Each consultation is powered by an intelligent matching engine that connects patients to the most qualified cancer specialists based on their diagnosis and clinical profile.
“The platform organizes imaging, pathology reports, and medical records in line with NCCN® guidelines before the consultation even begins,” Matteotti says. “That means our physicians can focus entirely on clinical insight and personalized care.”
By standardizing data preparation and integrating real-world evidence, Trusted Telehealth® ensures that every opinion reflects the most current oncology science. Patients gain clarity, confidence, and, often, new treatment pathways, including clinical trials they might otherwise never discover.
AI Meets Empathy in Oncology
While the ISMIOS™ engine exemplifies the sophistication of AI in healthcare, Matteotti emphasizes that technology is only as powerful as the humanity behind it. “We’re not replacing local physicians,” he says. “We are empowering them to work together with us in the interest of the patient.”
That collaborative ethos is central to Matteotti’s philosophy. Having led global programs for pancreatic and liver cancers, he recognizes that the future of cancer care will be defined not just by new molecules but by new models of connection. Through Trusted Telehealth®, oncologists and community physicians collaborate across institutions and time zones, creating what Matteotti calls “a continuum of expertise.”
The approach allows local clinicians to maintain primary responsibility while integrating subspecialty insights that enhance decision-making. “It’s life-changing care delivered digitally with a human touch,” he adds.
Global Strategy Meets Local Impact
At Bristol Myers Squibb, he led global launch readiness, real-world evidence strategies, and medical data planning across major oncology markets in the US, Europe, and Asia Pacific. His initiatives, such as the NextGen-PDAC working group, have advanced precision oncology through AI integration and the utilization of legacy data.
That experience informs his belief that digital platforms like Trusted Telehealth® are essential extensions of modern cancer infrastructure. “Second opinions should never be a privilege. They should be a standard of care,” Matteotti asserts. “And longitudinal cancer care should be a must.”
With HIPAA and SOC 2 compliance, the Trusted Telehealth® system scales securely and consistently across healthcare networks. Its structure makes it possible to bring the same level of oncologic expertise found in major academic centers to patients in remote or underserved regions.
His vision is to create a world where every cancer patient can make informed choices backed by evidence and empathy. “We are making that vision real,” Matteotti says. “Bringing world-class oncology expertise to every zip code in America, and beyond.”
For more insights from Dr. Ronald Matteotti, connect with him on LinkedIn. Get in touch with us at www.tth.ai
